Chellaram Foundation is a “Not-For-Profit” organization in India founded by Mr Lal L Chellaram in 2007. Chellaram Diabetes Institute – CDI (www.cdi.org.in), a unit of Chellaram Foundation, started in the year 2011, is one of the most prominent Diabetes treatment, research and teaching establishments with the main objective of creating an IMPACT on the rising burden of Diabetes in India.
The vision is achieved through four pillars, viz. Patient Care, Education, Research and Awareness. In addition, CDI operates an ambitious Rural Outreach Programme that combines all the four pillars, to take the programme to the doorstep of the underprivileged rural population.
CDI is a recognised Scientific and Industrial Research Organization (SIRO) by the Department of Scientific and Industrial Research (DSIR) and the Centre of Excellence in Diabetes Care by the International Diabetes Federation (IDF).
Chronicle of Diabetes Research and Practice is a Flagship Journal of the Chellaram Diabetes Institute (www.cdi.org.in) published twice a year in organized volumes by Medknow (Wolters Kluwer), one of the largest open access publishers. Each issue could include Original Articles, Brief Communications, Case reports, Review Articles, Letter to Editors and Commentaries. The Journal does not charge for submission, processing or publication of manuscripts and for colour reproduction of photographs.
Chronicle of Diabetes Research and Practice is an open access, peer reviewed online and print Journal with a focus to address the unique challenges in Diabetology by publishing articles covering all areas of Diabetes & its complications, and related disorders. The Journal provides a platform for Healthcare Professionals, Clinical and Basic Researchers, Diabetes Educators and all Allied Professionals working in the field of Diabetes to submit original research and other articles.
Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp
Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.
Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.
CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:
- "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
- The Editorial Board has full and final approval over the content of all advertisements.
- Advertisers will never be shown any manuscripts or other content prior to publication.